Background The treatment of stage I and II non-small cell lung cancer (NSCLC) in patients
with good or low surgical risk is primarily surgical resection. However, this area is …

Background The surgical treatment of stage I and II non-small cell lung cancer (NSCLC)
continues to evolve in the areas of intraoperative lymph node staging (specifically the issue …

Objectives Stage III non-small cell lung cancer (NSCLC) describes a heterogeneous
population with disease presentation ranging from apparently resectable tumors with occult …

Background The standard treatment of stage I non-small cell lung cancer (NSCLC) is
lobectomy with systematic mediastinal lymph node evaluation. Unfortunately, up to 25% of …

The American Joint Committee on Cancer defines stage I non-small cell lung carcinoma
(NSCLC) as consisting of patients with a T1 or T2 primary tumor designation and no …

Study objectives Stage IIIA non-small cell lung cancer represents a relatively heterogeneous
group of patients with metastatic disease to the ipsilateral mediastinal (N2) lymph nodes and …

Background Stage IV non-small cell lung cancer (NSCLC) is a treatable, but not curable,
clinical entity in patients given the diagnosis at a time when their performance status (PS) …

The incidence of stage I and II nonsmall cell lung cancer is likely to increase with the ageing
population and introduction of screening for high-risk individuals. Optimal management …

Lung cancer is still the leading cause of cancer death worldwide, and non-small cell lung
cancer accounts for 80% to 85% of all lung cancer cases. Surgery, radiation therapy, and …

Surgery serves an important role in the diagnosis, staging, and definitive management of
non–small cell lung cancer (NSCLC). Resection is the primary mode of treatment for stage I …